{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:04:46Z","timestamp":1793459086009,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["G1403"],"award-info":[{"award-number":["G1403"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/PO2730X\/1"],"award-info":[{"award-number":["MR\/PO2730X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N028651\/1"],"award-info":[{"award-number":["MR\/N028651\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kattan Trust Charity 285","award":["RCF207\/TS\/2015"],"award-info":[{"award-number":["RCF207\/TS\/2015"]}]},{"name":"Kattan Trust Charity 285","award":["RCF103\/AS\/2014"],"award-info":[{"award-number":["RCF103\/AS\/2014"]}]},{"DOI":"10.13039\/501100012317","name":"NIHR University College London Hospitals Biomedical Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.expneurol.2017.09.010","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T03:31:39Z","timestamp":1505791899000},"page":"180-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"PB","title":["Insights into the structural biology of Gaucher disease"],"prefix":"10.1016","volume":"298","author":[{"given":"Laura","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony H.V.","family":"Schapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2017.09.010_bb0005","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new Glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0010","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","article-title":"Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews","volume":"351","author":"Aharon-Peretz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0015","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/brain\/awv179","article-title":"Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations","volume":"138","author":"Alcalay","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0020","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bcmd.2003.10.010","article-title":"Expression and functional characterization of mutated glucocerebrosidase alleles causing Gaucher disease in Spanish patients","volume":"32","author":"Alfonso","year":"2004","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10038-007-0135-4","article-title":"Mutation analysis and genotype\/phenotype relationships of Gaucher disease patients in Spain","volume":"52","author":"Alfonso","year":"2007","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0030","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/prot.21554","article-title":"An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease","volume":"70","author":"Atrian","year":"2008","journal-title":"Proteins"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0035","article-title":"Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation","volume":"47","author":"Bae","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamaneurol.2014.2950","article-title":"Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort","volume":"72","author":"Beavan","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.WNL.0000072482.70963.D7","article-title":"Gaucher's disease with Parkinson's disease - clinical and pathological aspects","volume":"61","author":"Bembi","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0050","doi-asserted-by":"crossref","DOI":"10.1021\/acschembio.7b00276","article-title":"Stabilization of glucocerebrosidase by active-site occupancy","author":"Ben Bdira","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2010.10.012","article-title":"Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant","volume":"46","author":"Bendikov-Bar","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0060","doi-asserted-by":"crossref","first-page":"14861","DOI":"10.1016\/S0021-9258(18)82412-7","article-title":"Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity","volume":"268","author":"Berg-Fussman","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0065","first-page":"741","article-title":"Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts","volume":"44","author":"Bergmann","year":"1989","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0070","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bcmd.2005.07.005","article-title":"Hematologically important mutations: Gaucher disease","volume":"35","author":"Beutler","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0021-9258(18)97611-8","article-title":"The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue","volume":"240","author":"Brady","year":"1965","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0080","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1107\/S0907444906038303","article-title":"Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease","volume":"62","author":"Brumshtein","year":"2006","journal-title":"Acta Crystallogr. Sect. D"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0085","doi-asserted-by":"crossref","first-page":"29052","DOI":"10.1074\/jbc.M705005200","article-title":"Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease","volume":"282","author":"Brumshtein","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cell.2006.04.014","article-title":"Molecular chaperones and protein quality control","volume":"125","author":"Bukau","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF02263575","article-title":"Genetic heterogeneity of membrane-bound beta-glucosidase in Gaucher's disease","volume":"4","author":"Carroll","year":"1981","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bcmd.2005.04.007","article-title":"Perinatal lethal phenotype with generalized ichthyosis in a type 2 Gaucher disease patient with the [L444P;E326K]\/P182L genotype: effect of the E326K change in neonatal and classic forms of the disease","volume":"35","author":"Chabas","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0110","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0115","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1742-4658.2006.05181.x","article-title":"Protein-misfolding diseases and chaperone-based therapeutic approaches","volume":"273","author":"Chaudhuri","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0014-5793(99)00090-3","article-title":"Crystal structure of the beta-glycosidase from the hyperthermophile Thermosphaera aggregans: insights into its activity and thermostability","volume":"445","author":"Chi","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0167-4838(86)90010-5","article-title":"In situ radiation-inactivation size of fibroblast membrane-bound acid beta-glucosidase in Gaucher type 1, type 2 and type 3 disease","volume":"870","author":"Choy","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2012.10.010","article-title":"Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage","volume":"62","author":"Cleeter","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0135","series-title":"Sphingolipids and Metabolic Disease","author":"Cowart","year":"2011"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0140","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1042\/bj2260283","article-title":"Functional lysosomal hydrolase size as determined by radiation inactivation analysis","volume":"226","author":"Dawson","year":"1985","journal-title":"Biochem. J."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0150","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1111\/j.1582-4934.2011.01374.x","article-title":"Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders","volume":"15","author":"Doyle","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/mds.25248","article-title":"The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease","volume":"28","author":"Duran","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0160","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/sj.embor.embor873","article-title":"X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease","volume":"4","author":"Dvir","year":"2003","journal-title":"EMBO Rep."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1051\/jbio\/2002196020151","article-title":"The active site of human glucocerebrosidase: structural predictions and experimental validations","volume":"196","author":"Fabrega","year":"2002","journal-title":"J. Soc. Biol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0170","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10545-008-0868-z","article-title":"Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher registry","volume":"31","author":"Fairley","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0175","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","article-title":"ER stress and autophagic per turbations lead to elevated extracellular alpha-synuclein in GBA-N370S LEParkinson's iPSC-derived dopamine neurons","volume":"6","author":"Fernandes","year":"2016","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0180","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jsb.2015.07.002","article-title":"Short-time dynamics of pH-dependent conformation and substrate binding in the active site of beta-glucosidases: a computational study","volume":"191","author":"Flannelly","year":"2015","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0185","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0190","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0195","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0200","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0950-3536(97)80032-7","article-title":"Gaucher's disease: molecular, genetic and enzymological aspects","volume":"10","author":"Grabowski","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10409239009090616","article-title":"Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease","volume":"25","author":"Grabowski","year":"1990","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0210","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0006-291X(90)92388-G","article-title":"Human acid beta-glucosidase - glycosylation is required for catalytic activity","volume":"168","author":"Grace","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0215","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/S0021-9258(17)42166-1","article-title":"Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression","volume":"269","author":"Grace","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0220","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1073\/pnas.68.11.2810","article-title":"Gaucher's disease: deficiency of \u201ccid\u201d \u03b2-glucosidase and reconstitution of enzyme activity in vitro","volume":"68","author":"Ho","year":"1971","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0225","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/(SICI)1098-1004(1998)12:4<240::AID-HUMU4>3.0.CO;2-J","article-title":"Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population","volume":"12","author":"Horowitz","year":"1998","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2011.07.002","article-title":"The enigma of the E326K mutation in acid beta-glucocerebrosidase","volume":"104","author":"Horowitz","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0235","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0240","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14789450.2016.1174583","article-title":"Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease","volume":"13","author":"Jung","year":"2016","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0245","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1515\/BC.2008.163","article-title":"Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy","volume":"389","author":"Kacher","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0250","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1007\/s00018-010-0399-2","article-title":"\u03b2-Glucosidases","volume":"67","author":"Ketudat Cairns","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0255","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0260","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0265","article-title":"Essential cell biology: an introduction to the molecular biology of the cell","volume":"393","author":"Latchman","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0270","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/mgme.2000.3035","article-title":"Fate and sorting of acid beta-glucosidase in transgenic mammalian cells","volume":"70","author":"Leonova","year":"2000","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0275","first-page":"973231","article-title":"A guided tour of the structural biology of Gaucher disease: acid-beta-glucosidase and Saposin C","volume":"2011","author":"Lieberman","year":"2011","journal-title":"J. Enzym. Res."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0280","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0285","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0290","series-title":"Lipid Storage Disorders: Biological and Medical Aspects","first-page":"353","article-title":"Splenic glucocerebrosidase and its cytosolic activator protein: effects on substrate hydrolysis and covalent inhibition by conduritol B epoxides","author":"Liedtke","year":"1988"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0295","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/gm566","article-title":"Genetics and genomics of Parkinson's disease","volume":"6","author":"Lin","year":"2014","journal-title":"Genome Med."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0300","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ymgme.2011.12.002","article-title":"Is E326K glucocerebrosidase a polymorphic or pathological variant?","volume":"105","author":"Liou","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0305","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1074\/jbc.M511110200","article-title":"Analyses of variant acid beta-glucosidases - effects of Gaucher disease mutations","volume":"281","author":"Liou","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0310","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Luan","year":"2013","journal-title":"Brain and Development"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0315","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0320","first-page":"2712","article-title":"The contribution of mutant GBA to the development of Parkinson disease in Drosophila","volume":"25","author":"Maor","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0325","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0014-5793(83)80943-0","article-title":"Modification of subunit interaction in membrane-bound acid beta-glucosidase from Gaucher disease","volume":"160","author":"Maret","year":"1983","journal-title":"FEBS Lett."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0330","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0335","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0340","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/jnnp-2012-302402","article-title":"A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers","volume":"83","author":"McNeill","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0345","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0350","doi-asserted-by":"crossref","first-page":"10975","DOI":"10.1016\/S0021-9258(19)78077-6","article-title":"Identification of Glu(340) as the active-site nucleophile in human glucocerebrosidase by use of electrospray tandem mass-spectrometry","volume":"269","author":"Miao","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0355","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cccn.2004.01.010","article-title":"Biochemical study on beta-glucosidase in individuals with Gaucher's disease and normal subjects","volume":"343","author":"Michelin","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0360","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jnc.13385","article-title":"The relationship between glucocerebrosidase mutations and Parkinson disease","volume":"139","author":"Migdalska-Richards","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0365","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice","volume":"80","author":"Migdalska-Richards","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/syn.21967","article-title":"Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate","author":"Migdalska-Richards","year":"2017","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0375","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1016\/j.febslet.2006.04.096","article-title":"Reexamination of the cysteine residues in glucocerebrosidase","volume":"580","author":"Moharram","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0380","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0385","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0390","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12033-010-9303-4","article-title":"Generation of polyclonal antibodies against recombinant human glucocerebrosidase produced in Escherichia coli","volume":"46","author":"Novo","year":"2010","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0395","doi-asserted-by":"crossref","first-page":"42105","DOI":"10.1074\/jbc.M110.172098","article-title":"Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S","volume":"285","author":"Offman","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0400","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/protein\/gzr032","article-title":"Comparison of a molecular dynamics model with the X-ray structure of the N370S acid-beta-glucosidase mutant that causes Gaucher disease","volume":"24","author":"Offman","year":"2011","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0405","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.4161\/auto.25878","article-title":"Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases","volume":"9","author":"Osellame","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0410","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/mds.25772","article-title":"Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease","volume":"29","author":"Parnetti","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0415","series-title":"GeneReviews (R), Seattle (WA)","article-title":"Gaucher disease","author":"Pastores","year":"1993"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0420","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/S0021-9258(19)43595-3","article-title":"Isolation and characterization of glucocerebrosidase from human placental tissue","volume":"248","author":"Pentchev","year":"1973","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0425","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10719-016-9661-7","article-title":"Glycosylation is crucial for a proper catalytic site organization in human glucocerebrosidase","volume":"33","author":"Pol-Fachin","year":"2016","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0430","doi-asserted-by":"crossref","first-page":"23815","DOI":"10.1074\/jbc.M502799200","article-title":"X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease","volume":"280","author":"Premkumar","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0435","first-page":"158","article-title":"Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease","volume":"32","author":"Raghavan","year":"1980","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0440","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0445","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/BJ20050325","article-title":"The N370S (Asn370\u2192Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C","volume":"390","author":"Salvioli","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0450","first-page":"6","article-title":"Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models","author":"Sanchez-Martinez","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0455","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0460","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/cb600187q","article-title":"Chemical chaperones and permissive temperatures alter the cellular localization of Gaucher disease associated glucocerebrosidase variants","volume":"1","author":"Sawkar","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0465","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1073\/pnas.1300822110","article-title":"Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease","volume":"110","author":"Schapira","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0470","first-page":"273","article-title":"Gaucher disease: insights from a rare Mendelian disorder","volume":"14","author":"Sidransky","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0475","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","article-title":"The link between the GBA gene and parkinsonism","volume":"11","author":"Sidransky","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0480","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multi-center analysis of glucocerebrosidase mutations in Parkinson disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0485","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0490","doi-asserted-by":"crossref","first-page":"F163","DOI":"10.1136\/fn.82.2.F163","article-title":"Type 2 Gaucher disease: the collodion baby phenotype revisited","volume":"82","author":"Stone","year":"2000","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0495","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0021-9673(01)87969-3","article-title":"Rapid molecular-weight determination for native Glucocerebrosidase from human-placenta using high-performance liquid-chromatography","volume":"261","author":"Strasberg","year":"1983","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069147","article-title":"Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in drosophila eye","volume":"8","author":"Suzuki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0505","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2012.04.024","article-title":"The role of saposin C in Gaucher disease","volume":"106","author":"Tamargo","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0510","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.chembiol.2014.06.008","article-title":"ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease","volume":"21","author":"Tan","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0515","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","article-title":"Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?","volume":"79","author":"Tayebi","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0520","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20130081","article-title":"Glycosylation and functionality of recombinant beta-glucocerebrosidase from various production systems","volume":"33","author":"Tekoah","year":"2013","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0525","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/hmg\/ddq204","article-title":"Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting","volume":"19","author":"Vaccaro","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0530","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1074\/jbc.M110.150433","article-title":"X-ray and biochemical analysis of N370S mutant human acid beta-glucosidase","volume":"286","author":"Wei","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0535","doi-asserted-by":"crossref","first-page":"30271","DOI":"10.1074\/jbc.273.46.30271","article-title":"Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators","volume":"273","author":"Wilkening","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0540","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13068-016-0560-8","article-title":"Engineering a highly active thermophilic beta-glucosidase to enhance its pH stability and saccharification performance","volume":"9","author":"Xia","year":"2016","journal-title":"Biotechnol. Biofuels"},{"key":"10.1016\/j.expneurol.2017.09.010_bb0545","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.stemcr.2017.01.011","article-title":"A human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers","volume":"8","author":"Yang","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0550","doi-asserted-by":"crossref","first-page":"28080","DOI":"10.1074\/jbc.M111.237859","article-title":"Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases","volume":"286","author":"Yap","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0555","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymgme.2012.11.010","article-title":"Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity","volume":"108","author":"Yap","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0560","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1074\/jbc.M114.610584","article-title":"Structural features of membrane-bound glucocerebrosidase and alpha-synuclein probed by neutron reflectometry and fluorescence spectroscopy","volume":"290","author":"Yap","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0565","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ajh.23118","article-title":"Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation","volume":"87","author":"Zhang","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.expneurol.2017.09.010_bb0570","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms5321","article-title":"Lysosome sorting of beta-glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor","volume":"5","author":"Zhao","year":"2014","journal-title":"Nat. Commun."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488617302406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488617302406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:16:35Z","timestamp":1659485795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488617302406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":114,"alternative-id":["S0014488617302406"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2017.09.010","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights into the structural biology of Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2017.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}